Neuroone Medical Technologies CORP Schedule 13G passive stakes

Brian and Barbara Pratt jointly report beneficial ownership of 1,085,934 shares, representing 12.5% of NeuroOne Medical Technologies Corporation's common stock.

Brian and Barbara Pratt have filed a Schedule 13G disclosing a 7.4% beneficial ownership stake in NeuroOne Medical Technologies Corporation.

Sio Capital Management, LLC has filed an amended Schedule 13G, reporting a beneficial ownership of 4.72% in NeuroOne Medical Technologies Corp as of September 30, 2025.

Bleichroeder LP and affiliates report a passive 8.03% beneficial ownership stake in NeuroOne Medical Technologies.

Sio Capital Management, LLC has disclosed a 7.07% beneficial ownership stake in NeuroOne Medical Technologies Corp, holding 3,523,663 common shares.

Laurence W. Lytton has filed an amended Schedule 13G, disclosing a 2.6% beneficial ownership stake in NeuroOne Medical Technologies Corp., held for passive investment purposes.

AWM Investment Company, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 4.8% in NeuroOne Medical Technologies Corp, totaling 2,354,167 shares.

An amended Schedule 13G filing reveals that Manchester Explorer, L.P., Manchester Management Company, LLC, Manchester Management PR, LLC, James E. Besser, and Morgan C. Frank continue to hold significant, yet passive, beneficial ownership in NeuroOne Medical Technologies Corp., with all reported stakes remaining below the 5% threshold.

Merchant Adventure Fund, L.P. has reported a passive beneficial ownership of 13.6% in NeuroOne Medical Technologies Corp., holding 4,200,000 shares of common stock as of December 31, 2024.